Compare Dover Corp (DOV) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs Tango Therapeutics Inc. — how do they compare? Dover Corp trades at $193.04 (market cap $25.92B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Dover Corp is far larger — about 6.9× Tango Therapeutics Inc.'s market cap, and Dover Corp pays a 1.09% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dover Corp for 74 Days and Tango Therapeutics Inc. for 0 Days on average.
| DOV | TNGX | |
|---|---|---|
Market Cap | $25.92B | $3.75B |
Volume | 807,452 | 9,619,106 |
Sector | Industrials | Health |
52-Week High | $233.31 | $32.90 |
52-Week Low | $162.66 | $7.50 |
Typical Hold Time | 74 Days | 0 Days |
Enterprise Value | $27.43B | $2.77B |
Dividend Yield | 1.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dover Corporation (DOV) trades at $193.33, up 1.28% with strong analyst consensus of 19 Buy ratings and no Sell recommendations. The stock shows solid fundamentals with consistent earnings beats, 13.48% net margin, and robust cash flow. Recent acquisitions and product launches position the company for growth, while technical indicators suggest neutral momentum near key resistance at $195.
Outlook remains positive with 67.9% analyst Buy rating and $243.20 price target representing 26% upside. Risks include integration challenges from recent acquisitions and industrial sector volatility. The company's Dividend King status and strong balance sheet provide stability amid market fluctuations.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
